Wellspring Biosciences, Inc., a wholly owned subsidiary of Araxes Pharma, LLC, received clearance from the U.S. FDA for an investigational new drug (IND) application for ARS-3248, a small molecule KRAS G12C inhibitor. ARS-3248 was discovered as part of an exclusive drug discovery and development agreement with Janssen Biotech, Inc, which will conduct the Phase I trial and have sole responsibility for clinical development. “Although KRAS was considered an undruggable target when we initi...